

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number
WO 01/58453 A1

- (51) International Patent Classification⁷: **A61K 31/55**, A61P 25/20
- (21) International Application Number: PCT/EP01/01221
- (22) International Filing Date: 6 February 2001 (06.02.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
00200499.2 11 February 2000 (11.02.2000) EP
- (71) Applicant (for all designated States except US): **AKZO NOBEL N.V.** [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **RUIGT, Gerardus, Stephanus, Franciscus** [NL/NL]; Monsterstraat 6, NL-5341 EB Oss (NL). **VAN DEN BERG, Frans** [NL/NL]; Franciscushof 13, NL-4133 BA Vianen (NL).
- (74) Agent: **KRAAK, Hajo**; Patent Department, Wethouder van Eschstraat 1, P.O.B. 20, NL-5340 BH Oss (NL).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/58453 A1

(54) Title: THE USE OF MIRTAZAPINE FOR THE TREATMENT OF SLEEP DISORDERS

(57) Abstract: The invention relates to the use of mirtazapine for the preparation of a medicine for a new method of treatment of a sleep disorder in a subject, which treatment comprises the administration of mirtazapine with a unit treatment dose comprising between 0.1 and 5 mg mirtazapine and relates to a patient pack for the treatment of sleep disorders.

The use of mirtazapine for the treatment of sleep disorders.

The invention relates to the use of mirtazapine for the preparation of a medicine for a new method of treatment of a sleep disorder in a subject.

5

Sleep difficulties are a major motivation for use of drugs. The most often selected drugs are those interacting with the GABA neurotransmitter-receptor system in the brain, the so-called minor tranquillisers, of which the group of benzodiazepine drugs is the classic example. Disadvantages of currently available hypnotics are the potential for adverse reactions, remaining lesser quality of sleep, hangover effects, dependency potential, withdrawal effects and undesirable effects on cognitive functioning. The quality of sleep can not only be derived from the effect of sleep, for example whether the sleep has been refreshing and has a positive effect on daytime drowsiness/alertness the morning after, but also from objective EEG determined characteristics, describing sleep stages and architecture.

The discovery of different types of benzodiazepine receptors are exploited to open new avenues for pharmaco-therapy of insomnia (for review see C.K.Kirkwood; Management of insomnia; J Am Pharmaceut. Ass. Vol 39 pp 688-696; 1999). Other mechanisms for inducing sleep are also explored. The opiate-like drugs, the barbiturates and anti-histamines are drug classes which have been used several decades ago as sleep inducers, but their use became obliterated due to undesirable side effects and/or lesser efficacy. Such drugs are still in use for other disorders whereby the main effects would be side effects when used for the treatment of sleep disorders. Specifically, drugs, antagonising histamine receptors are sedative and sleep inducing but are not used regularly anymore for the treatment of sleep disorders in view of lower selectivity, lower potency and lower safety in comparison to benzodiazepines and their modern successors.

Mirtazapine is known as an anti-depressant. It is active for that purpose at daily doses of 15-45 mg per person. It is well-known that the dose is crucial for effective therapy, in particular for the treatment of depression. Mirtazapine is reported to have some initial sedative effects and because

2

of this its effects on sleep have been investigated. It is reported that in the dose range of 5-30 mg per person per day improvement of transient, or situational insomnia is found, whereby the dose of 15 mg was reported to be preferable over 5 mg (Sørensen et al. Acta Psychiatr. Scand. 71: 339-346; 1985). Also Winokur (Biological Psychiatry 1998; 45(8S): p 106S) investigates 15 and 30 mg mirtazapine in depressed patients with prominent sleep related complaints and recommends further investigation of these doses for treatment of sleep disorders.

- 10 It has now been found that mirtazapine can be used for the preparation of a medicine for the treatment of a sleep disorder in a subject, which treatment comprises the administration of mirtazapine with a unit treatment dose comprising more than 0.1 and less than 5 mg mirtazapine, which in other words is a unit treatment dose (within the
15 range) between 0.1 and 5 mg mirtazapine.

In general this amounts for an average human person to a treatment dose in the range between 0.005 and 0.07 mg/kg.

- 20 In contrast to the expectations, the favourable results which make the compound available as a valid alternative for known drugs of choice for the treatment of sleep disorders were obtained with treatment doses below the dose range studied and recommended by Sørensen et al. and Winokur (cited above). At least for individual patients mirtazapine in the
25 above indicated dose range can be a better choice than a choice of one of the known sleep improving drugs in view of a better quality of sleep after treatment.

- The amounts of mirtazapine defined in this description refer to the
30 amount of free base of mirtazapine. Mirtazapine contains a centre of chirality and can exist as stereoisomers. The present invention includes the aforementioned stereoisomers within its scope and each of the individual (R) and (S) enantiomer and their salts, substantially free, i.e. associated with less than 5%, preferably less than 2%, in particular less
35 than 1% of the other enantiomer and mixtures of such enantiomers in

any proportions including racemic mixtures containing substantially equal amounts of the two enantiomers.

The subject amenable for a treatment made available by this invention
5 can be an animal or a human person. This invention is preferably to be applied for a mammal and more preferably for a human person. Men and women often respond differently to drug treatment and suffer differently in nature, frequency and severity from sleep disorders. Also, there are differences in treatment methods for persons with sleep problems among
10 different age groups. The elderly, adolescents or postmenopausal age groups have different needs for treatment. Certain aspects of sleep quality improvement are more important for different age groups or gender or different sleep disturbances. Such differential factors are to be taken into account in selecting the treatment of this invention and in
15 selecting the exact dose of mirtazapine for the treatment. The very exact dose and regimen of mirtazapine administration will necessarily depend on the needs of the individual subject to whom it is being administered in the form of a medicament and on the nature or needs of the sleep disorder and the judgement of the medical practitioner. In general,
20 parenteral administration requires lower dosages than other methods of administration which are more dependent upon absorption. However, the daily dosages are between 0.005 and 0.07 mg/kg body weight of the recipient. The recipient is the subject receiving the dose of mirtazapine for treatment of a sleep disorder.

25

There are several types of sleep disorders in man, of which primary insomnia is the most common one and preferably selected to be treated with a low dose of mirtazapine according to this invention. Other sleep disorders are for example transient sleep disorders and secondary sleep
30 disorders. The sleep disorders can be diagnosed according to the criteria and methods outlined in the Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM IV) published by the American Psychiatric Association, Washington, D.C. (1994).

35 While it is possible to administer mirtazapine, or a pharmaceutical acceptable acid addition salt or solvate thereof, alone it is preferable to

present it as a pharmaceutical composition adapted for the treatment of sleep disorders, comprising the mirtazapine, or a pharmaceutically acceptable acid addition salt or solvate thereof, mixed with one or more pharmaceutically acceptable auxiliaries.

- 5 The medicament comprising mirtazapine may be administered enterally (e.g. orally, rectal nasal or topically) or parenterally (e.g. via intramuscular, subcutaneous, intravenous or intraperitoneal injections).

- A unit treatment dose (= a dosing unit) is an amount of mirtazapine in a
10 pharmaceutical presentation form for administration to a subject at a particular point in time. A daily treatment dose can be administered in one or more dosage units suitable for example for the oral, the rectal, the sublingual or the nasal route or through the skin (for example, transdermal patches, or in the form of a cream).

- 15 The invention further includes a patient pack for treatment of sleep disorders comprising dose units in combination with packaging material suitable for said dose units, whereby the dose units comprise pharmaceutical auxiliaries and mirtazapine in an amount between 0.1
20 and 5 mg and optionally, said packaging material is including means to help a recipient using the dose units most suitably for the treatment of a sleep disorder. Such means to help a recipient using the dose units most suitably for the treatment as described before herein are, for example, instructions for the use of the composition. In such a patient pack the
25 intended use of a formulation comprising mirtazapine for the treatment of sleep disorders can be inferred by instructions, facilities, provisions, adaptations and/or other means to help using the formulation most suitably for the treatment. Such measures make a patient pack specifically suitable for and adapted for use for treatment of a sleep
30 disorder.

- For making means of dosing, such as pills, tablets, suppositories, (micro-)capsules, powders, emulsions, creams, ointments, implants, a patch, a gel, and any other preparation for sustained release, sprays,
35 injection preparations in the form of a solution or suspension, suitable

auxiliaries such as carriers, fillers, binders, lubricants, dispersants, emulsifiers, stabilisers, surfactants, anti-oxidants, colorants, preservatives and the like can be used e.g. as described in the standard reference, Gennaro et al., Remington's Pharmaceutical Sciences, (18th ed., Mack Publishing Company, 1990, see especially Part 8:

Pharmaceutical Preparations and Their Manufacture). In general any pharmaceutically acceptable auxiliary which does not interfere with the function of the active compounds is suitable and can be used.

- 10 Suitable fillers or carriers with which the compositions can be administered include agar, alcohol, fats, lactose, starch, cellulose derivatives, polysaccharides, polyvinylpyrrolidone, silica, sterile saline and the like, or mixtures thereof used in suitable amounts.
- 15 Binders are agents used to impart cohesive properties to a pharmaceutical composition resulting in minimal loss from the pharmaceutical composition during production and handling. Binders are for example cellulose, starches, polyvinylpyrrolidone, and the like.
- 20 A suitable lubricant with which the active agent of the invention can be administered is, for example, magnesium stearate.

Surfactants are agents facilitating the contact and migration of compounds in different physical environments such as hydrophilic and hydrophobic environments. Many surfactants are known in the art of making pharmaceutical compositions as for example described in chapter 19 of Remington's Pharmaceutical Sciences (18th edition Editor A.R. Gennaro; Mack Publishing Comp; Easton, Pennsylvania). Surfactants that can be used during the process of preparing the pharmaceutical formulation are, for example, polyethylene glycol (PEG), and the like.

Mirtazapine may be prepared using the method described in US 4,062,848 which is incorporated herein by reference.

- 35 The following example is an illustration of the use of mirtazapine according to the invention.

Example

Mirtazapine is formulated in dosing units containing 0.5 mg, 1.5 mg and 5 4.5 mg mirtazapine.

The dosing units containing 0.5 mg (as tablets) have the composition as indicated in table 1:

Table 1

| | Per tablet | Per batch |
|------------------------|------------|--------------|
| Tablet excipients | in mg | in gram |
| Mirtazapine | 0.5 | 7.7 |
| Corn starch | 6.5 | 100.0 |
| Hydroxypropylcellulose | 1.3 | 20.0 |
| Magnesium stearate | 0.4875 | 7.5 |
| Aerosil | 0.975 | 15.0 |
| Lactose 200 M | to 65 mg | to 1000 gram |

10

For preparation of tablets a 1000 g granulate batch with the composition indicated in table 1 was prepared by premixing the complete amount of mirtazapine (base) with 100 gram of lactose 200 M in a 1 litre glass container for 10 minutes on a Turbula mixer at 22 rotations per minute 15 (rpm). The mixture is sieved through a 150 µm sieve before and after which a further 20 g of lactose 200 M is added. Granulation was performed in a high shear mixer granulator with the rest of the lactose, corn starch and hydroxypropyl-cellulose. The granulate was dried in a tray vacuum cabinet, classified with a conical screen mill and mixed with 20 aerosil and magnesium stearate. The 65 mg tablets were compressed with a diameter of 5 mm and a radius of convexity of 7.5 mm. Tablets with 1.5 and 4.5 mg mirtazapine were prepared similarly whereby the quantity of lactose was adapted in order to compensate for the increased quantity of mirtazapine.

25 Dosing units containing, 1.5 mg and 4.5 mg mirtazapine were prepared analogously with compensatory reduction of the amount of lactose 200 Mesh.

Effects of low dose mirtazapine on sleep in primary insomniac patients: a parallel double blind comparison with placebo and temazepam.

- 5 The study is a multi-centre study with participation of centres in several different countries in Europe.

Patients with primary insomnia are selected with diagnosis criteria according to DSM IV. Furthermore, patients should have 2 out of the
10 following three objective characteristics: patients with sleep latency ≥ 30 min, number of awakenings ≥ 3 per night, total sleep time $\leq 6,5$ out of 8 hours.

Major exclusion criteria are: secondary insomnia, sleep apnoea syndrome, non-related serious illness or drug abuse.

- 15 The study design is parallel, double blind, placebo and active controlled. Patients obtain treatment for 14 days with once daily administration of either 0.5 mg mirtazapine, 1.5 mg mirtazapine, 4.5 mg mirtazapine, 20 mg temazepam or placebo. Observations, assessments and measurements are recorded starting with one placebo treatment week
20 (wash-out) before the start of the treatment and ending with one placebo treatment week after the treatment to assess rebound/withdrawal. Assessment methods are poly-somnography (PSG) recordings for the nights of day - 2, -1, 1, 13, 14, 15, whereby night - 1 is defined to be the night immediately before the first day of the treatment. Subjective ratings
25 with rating scales for sleep and daytime functions (Leeds sleep evaluation questionnaire, MOS sleep rating scale, clinical global impression scale, Bastani mood rating scale, Lader Bond mood rating scale, profile of mood states) are performed with evening and morning questionnaires throughout the study period. Psychometric assessments are performed
30 on the mornings of day 1, 2 and day 15, whereby day 1 is defined to be the first day on which drug or placebo is administered in the evening. Blood is drawn on the mornings of day 1 and day 15 and on the evening of day 15 and assessments are made with recording of vital signs and physical examination and laboratory determinations. The improvement of
35 the quality, including efficacy of sleep and the safety, adverse effects and occurrence of rebound/withdrawal effects of the treatment with drugs is

observed in the changes before and after treatment of the various parameters measured with the indicated methods. Specifically the PSG assessments and subjective and objective assessment of sleep and performance the morning after, reveal information on sleep parameters, such as the functional EEG characteristics, the time falling asleep, total sleep time, the frequency and duration of night time awakenings, the time of early morning awakening, fragmentation of sleep, the sensitivity for disruptive stimuli, the feelings of refreshment, restlessness or tiredness after awakening, the sense of balance and co-ordination upon getting up, the sleep hygiene during day time (such as the occurrence of day time naps), the state of performance during daytime reflected in feeling tired, trouble in staying awake during the day, performance in cognitive tests such as simple reaction time, digit vigilance task, choice reaction time, rapid visual information processing, tracking, numeric working memory, word recognition, and daytime feelings of depressed mood, anxiety, confusion, anger, irritability and hangover effects. The Lader Bond mood rating scale provides daytime assessments separately along the dimensions alert/drowsy, calm/excited, strong/feeble, muzzy/clear-headed, well-co-ordinated/clumsy, lethargic/energetic, contented/discontented, troubled/tranquil, mentally slow/quick witted, tense/relaxed, attentive/dreamy, incompetent/proficient, happy/sad, antagonistic/amicable, interested/bored, withdrawn/gregarious, worried/carefree, depressed/elated and self-centered/outward-going. The Bastani visual analogue scale provides daytime assessments separately of the feelings sleepy, nauseated, dizzy, calm, active, anxious, irritable, depressed, good overall, restless, strange, aroused and mellow.

Claims

1. The use of mirtazapine for the preparation of a medicine for the treatment of a sleep disorder, which treatment comprises the administration of mirtazapine with a unit treatment dose comprising between 0.1 and 5 mg mirtazapine.
2. The use according to claim 1, characterised in that the sleep disorder is primary insomnia.
3. A method of treatment of a sleep disorder in a subject comprising the administration of an amount of mirtazapine, characterised in that the amount is between 0.1 and 5 mg mirtazapine.
4. The method of treatment according to claim 3, characterised in that the sleep disorder is primary insomnia.
5. A patient pack for treatment of sleep disorders comprising dose units in combination with packaging material suitable for said dose units, characterised in that the dose units comprise pharmaceutical auxiliaries and mirtazapine in an amount between 0.1 and 5 mg and optionally, said packaging material is including means to help a recipient using the dose units most suitably for the treatment of a sleep disorder.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 01/01221

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/55 A61P25/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | EP 0 813 873 A (AKZO NOBEL NV) 29 December 1997 (1997-12-29) column 1, line 47-49 --- | 1-5 |
| X | WO 99 25356 A (ANDREWS JOHN STUART ; AKZO NOBEL NV (NL)) 27 May 1999 (1999-05-27) page 3, line 19,20 --- | 1-5 |
| X | DATABASE DRUGNL 'Online! "Organon's Mirtazepine Still Available for Licensing in the USA" Database accession no. 92:603 XP002164421 the whole document & R&D FOCUS DRUG NEWS (13 JUL 1992), --- -/-- | 1-5 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

Date of the actual completion of the international search

22 May 2001

Date of mailing of the international search report

24/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Orviz Diaz, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/01221

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|---|-----------------------|
| X | E. VESTER ET AL.: "Anxiolytic and sleep improving effects of mirtazapine in everyday clinical practice" EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 7, no. SUPPL. 2, 1997, page S175 XP000981394 ISSN: 0924-977X abstract --- | 1-5 |
| X | RAMAEKERS J G ET AL: "Effects of nocturnal doses of mirtazapine and mianserin on sleep and on daytime psychomotor and driving performance in young, healthy volunteers." HUMAN PSYCHOPHARMACOLOGY, vol. 13, no. SUPPL. 2, November 1998 (1998-11), pages S87-S97, XP000979860 ISSN: 0885-6222 the whole document --- | 1-5 |
| X | RUIGT G S ET AL: "EFFECT OF THE ANTIDEPRESSANT ORG-3770 ON HUMAN SLEEP" EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol. 38, no. 6, 1990, pages 551-554, XP000979975 ISSN: 0031-6970 the whole document --- | 1-5 |
| X | WESTENBERG HERMAN G M: "Pharmacology of antidepressants: Selectivity or multiplicity?" JOURNAL OF CLINICAL PSYCHIATRY, vol. 60, no. SUPPL. 17, 1999, pages 4-8, XP000979957 ISSN: 0160-6689 the whole document --- | 1-5 |
| P,X | WINOKUR ANDREW ET AL: "Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: A pilot study." BIOLOGICAL PSYCHIATRY, vol. 48, no. 1, 1 July 2000 (2000-07-01), pages 75-78, XP000979897 ISSN: 0006-3223 the whole document --- | 1-5 |
| | --- -/-- | |

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/01221

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | THASE MICHAEL E: "Antidepressant treatment of the depressed patient with insomnia." JOURNAL OF CLINICAL PSYCHIATRY, vol. 60, no. SUPPL. 17, 1999, pages 28-31, XP000981397 ISSN: 0160-6689 the whole document ---- | 1-5 |
| X | SITSEN J M A ET AL: "Mirtazapine, a novel antidepressant, in the treatment of anxiety symptoms: Results from a placebo-controlled trial." DRUG INVESTIGATION, vol. 8, no. 6, 1994, pages 339-344, XP000981393 ISSN: 0114-2402 the whole document ----- | 1-5 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/01221

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| EP 0813873 A | 29-12-1997 | AU 727851 B | 04-01-2001 |
| | | AU 2612997 A | 08-01-1998 |
| | | BR 9703624 A | 01-09-1998 |
| | | CA 2208199 A | 19-12-1997 |
| | | CN 1173330 A | 18-02-1998 |
| | | CZ 9701870 A | 14-01-1998 |
| | | HU 9701068 A | 28-08-1998 |
| | | IL 121076 A | 31-10-2000 |
| | | JP 10067663 A | 10-03-1998 |
| | | NO 972816 A | 22-12-1997 |
| | | NZ 328113 A | 29-09-1999 |
| | | PL 320628 A | 22-12-1997 |
| | | SG 60073 A | 22-02-1999 |
| | | TR 9700522 A | 21-01-1998 |
| | | US 5977099 A | 02-11-1999 |
| WO 9925356 A | 27-05-1999 | AU 1754899 A | 07-06-1999 |
| | | BR 9815098 A | 10-10-2000 |
| | | CN 1278731 T | 03-01-2001 |
| | | EP 1030667 A | 30-08-2000 |
| | | NO 20002218 A | 12-05-2000 |
| | | PL 340467 A | 12-02-2001 |